Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
The invention concerns synthetic nutritional formulations, particularly milk based compositions, for infants and children. The compositions are especially adapted to the age of the child, younger or older than three months. The invention further relates to administration of these compositions for promoting the healthy establishment of cognitive function in infant boys and girls and in young boys and girls up to the age of thirty-six months.
1. A method for promoting a healthy establishment of cognitive function in an infant younger than three months old, the method comprising administering to the infant younger than three months old a synthetic nutritional composition comprising:
13.8-17 mg/100 ml of n-6 eicosatrienoic acid;
0.2-0.25 mg/100 ml of disialoganglioside-3 (GD-3); and
0.2-0.25 mg/100 ml of monosialoganglioside-3 (GM-3);
the GM-3 and the GD-3 in a GM-3:GD-3 ratio of 1.2 to 1.35.
2. The method of claim 1 , wherein the healthy establishment of cognitive function is measured according to at least one of Griffiths Scales or Bayley Scales.
3. The method of claim 1 , wherein:
the n-6 eicosatrienoic acid is 15.0-16.0 mg/100 ml of the synthetic nutritional composition;
the disialoganglioside-3 (GD-3) is 0.21-0.24 mg/100 ml of the synthetic nutritional composition;
the monosialoganglioside-3 (GM-3) is 0.21-0.23 mg/100 ml of the synthetic nutritional composition; and
the synthetic nutritional composition further comprises 8.2-8.7 mg/100 ml of sphingomyelin.
4. The method of claim 1 , wherein the infant had a birth weight less than 2500 g.
5. The method of claim 1 , wherein the synthetic nutritional composition further comprises 7.6-9.3 mg/100 ml of sphingomyelin.
6. The method of claim 1 , wherein the synthetic nutritional composition further comprises a phospholipid selected from the group consisting of:
5.4-6.6 mg/100 ml of phosphotitdylcholine;
6.0-7.5 mg/100 ml of phosphotitdylethanolamine;
1-1.2 mg/100 ml of phosphotitdylinositol; and
0.7-0.8 mg/100 ml of phosphotitdylserine.
7. The method of claim 1 , wherein the infant was small for gestational age.
8. The method of claim 1 , wherein the infant experienced intrauterine growth retardation.
9. The method of claim 1 , wherein the infant is suffering or suffered from cognitive function impairment during at least one of in utero, during birth, or after birth.